Skip to main content
National Cancer Institute Center for Cancer Research
  • CCR Central
  • Login

COVID-19 is an emerging, rapidly evolving situation. What people with cancer should know: https://www.cancer.gov/coronavirus. Get the latest public health information from CDC: https://www.coronavirus.gov. Get the latest research information from NIH: https://www.nih.gov/coronavirus.

  • Clinical Trials
  • Research
  • Training
  • Careers
  • News
  • About CCR
CCR Home » CCR Milestones - 2019 » By the Numbers
  • GovDelivery Link

By the Numbers


  • Email
  • Twitter
  • LinkedIn
  • Share on Facebook
  • Share on Pinterest

CCR by the Numbers

  • ~1,300Articles in Peer-Reviewed Journals
  • 1,346Trainees
  • 74New Employee Invention Reports
  • 36Issued U.S. Patents
  • 592Active Licenses
  • 30New Cooperative Research and Development Agreements (CRADAs)
  • 188Active CRADAs
  • 251Open Clinical Trials
  • 40New Trials Opened
  • 76New Technologies Licensed
  • 2,240New Patients
Turn The Pages Milestones 2018-2019 Magazine CoverFlippingBookImage View the FlipBook
Download CCR Milestones 2018-2019 PDF

Table of Contents

Home

  • Director's Note

  • Expanding the Kinase Universe

  • Releasing the Brakes on the Immune System

  • Training the Immune System to Remember HIV

  • Liver Tumors Link to the Microbiome

  • Moxe for Leukemia

  • Immunotherapy vs. Breast Cancer

  • Arresting Metastasis

  • Sorting Lymphoma Subtypes

  • Resetting the Ras Pathway

  • Predicting Immunotherapy Responses

  • Keeping DNA Replication in Check

  • Clotting the Spread of Cancer

  • Diving Deep into the Red

  • New Faculty

  • Awards & Honors

  • By the Numbers

 

NIH…Turning Discovery Into Health®

U.S. Department of Health and Human Services     |     National Institutes of Health     |     National Cancer Institute     |     USA.gov

Home  |  Contact  |  Policies  |  Accessibility  |  Viewing Files  |  FOIA

 

 

Ported to Drupal by Drupalizing a Project of More than Themes. Designed by Site5 WordPress Themes.